NattoPharma - Global Vitamin K2 Leader Committed to Quality

When choosing NattoPharma ASA as a strategic partner, a company is assured it will receive high-quality products and premium support.

NattoPharma, the world leader in Vitamin K2 research and development, has invested millions of dollars in in-vitro, in-vivo and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market.

Innovation

After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7, NattoPharma has consistently answered and met market needs through the development of new production technologies:

  • In 2012, the company introduced MenaQ7 Crystals, an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.

Key benefits:

  • 100% trans form assuring high absorption and bioavailability
  • more than 96% pure MK-7, ensuring high efficacy and safety
  • no cis-isomers, a biologically inactive form of the MK-7 molecule
  • free from soy and all known allergens
  • proven stable and with a 30-month shelf life.

The Crystals natural product range is broad and caters to a variation of needs. For instance, water-soluble and water-dispersible varieties are suitable for beverages or other liquid supplements.

  • NattoPharma introduced the only all-trans nature-identical synthesised Vitamin K2, MenaQ7 PURE, in the fall of 2014. This high-quality, competitively priced ingredient was recognised at Natural Products West/Engredea 2015 with the NutrAward for Best Functional Ingredient.

Key benefits:

  • all-trans nature-identical synthetic MK-7
  • more than 99% pure MK-7
  • absent of cis-isomers
  • guaranteed free from all known allergens
  • proven stable and with a three-year shelf life
  • cost-effective production enables a competitively priced MenaQ7.

A bioequivalence study shows that NattoPharma's natural MK-7 preparation and its nature-identical synthetic MK-7 are equivalent. The MenaQ7 PURE product line offers a complementary technology to the natural MenaQ7 Crystals products with the same technical and clinical benefits.

Clinical substantiation

NattoPharma has driven the knowledge of Vitamin K2's benefits through its relationships with international research institutes. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma's all-trans MK-7 products:

  • MenaQ7 for optimal bioavailability (Schurgers 2007; Sato 2012)
  • MenaQ7 in healthy populations (van Summeren 2009; Theuwissen 2012)
  • MenaQ7 for bone health (Knapen 2013; van Summeren 2009)
  • MenaQ7 for cardiovascular health (Dalmeijer 2012; Chatrou 2012; Theuwissen 2012; Knapen 2015)
  • MenaQ7 in diseased populations (Westenfeld 2012; Calwuè 2014)

Patents

NattoPharma continues to build its competitive advantage through its IPR focus and has patents both granted and pending related to relevant health benefits and market segments, creating extra value for its customers:

  • In 2012, NattoPharma was granted US and Canadian patents covering the use of Vitamin K2 (menaquinone-7) in foods and supplements for maintaining, optimising, strengthening or promoting cardiovascular health.
  • In 2014, NattoPharma was granted a new Canadian patent (US patent pending) for pharmaceutical and nutraceutical products providing Vitamin K2 in combination with one or more polyunsaturated fatty acids for benefits related to bone, cartilage and the cardiovascular system.
  • In Europe, NattoPharma thus far has three patents issued for the use of vitaminK2 for promoting cardiovascular health.

Regulatory knowledge and expertise

MenaQ7 was the first vitamin K2 to be introduced in the North American market and to achieve Novel Food status in Europe.

MenaQ7 Crystals meet the regulatory requirements in the US, EU, Australia and Asia for pure and safe Vitamin K2 product applicable in food supplements and functional foods.

MenaQ7 PURE meets exactly the same regulatory requirements as the natural MK-7 molecule - Novel Food in the EU, Self-Affirmed GRAS in the US - and complies with compositional guidelines for MK-7 in Australia and New Zealand.

Partnership ... from start to finish

From scientists to sales force, the NattoPharma team works to make its partners more effective. Further, marketing helps cultivate a company's message, and disseminate thelatest information to the industry, as well as the general public, ensuring NattoPharma's partners' products will be in demand.

Products and Services

Contact Details

NattoPharma
URL: www.nattopharma.com

MenaQ7 arterial stiffness chart - three-year study.
MenaQ7 BMC chart - three-year study.
NutrAward 2015 - Best Functional Ingredient.
Make An Enquiry
First Name

Last Name

Email Address

Enquiry


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.